Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD

Starting soon · Phase 2

Conditions studied: Immunoglobulin G4-related Disease

In brief

The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.

Key facts

Study ID

NCT07222553

Run by

Amgen

People needed

15

Starts

2026-07-31

Expected to finish

2031-06-10

Last updated by the study team

2026-05-04

Who can join

Age: 2 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.